Several murine monoclonal anti-human Factor VII antibodies were produced using hybridoma technology. Two noncompetitive monoclonal antibodies were used to examine by Western blotting the Factor VII cross-reactive material (CRM) in normal human plasma and three commercially available congenitally Factor VIIdeficient plasmas, and to construct a facile "sandwich" immunoassay for plasma Factor VII. A second, previously undescribed, form of Factor VII CRM was detected in human plasma, which on Western blotting stained with an apparent intensity 5-8% that of Factor VII. This glycoprotein, tentatively called VII*, has a molecular weight 4,500 D less than Factor VII, lacks detectable Factor VII functional activity, does not bind to barium citrate, and is not recognized by a monoclonal antibody that recognizes Factor VII but not a-chymotrypsin-treated Factor VII. VII* was not proteolytically produced from Factor VII during in vitro coagulation or after infusion of human Factor VII into rabbits. As determined by Western blotting, the human hepatoma cell line, HepG2, cultured in the presence of vitamin K, secreted relatively greater levels of VII* in proportion to VII (75%) than that found in human plasma. Warfarin treatment of HepG2 cells decreased the quantity of VII secreted by 77%, whereas it only inhibited the secretion of VII* by 14%. Immunologic studies of the plasmas from a patient on chronic warfarin therapy and an individual given a short course of high dose warfarin therapy corroborated the in vitro synthetic studies obtained with HepG2 cells. The data are consistent with the production of VII* by posttranslational, proteolytic, modification of VII, that, at least in the HepG2 cells studied, occurs intracellularly. However, other mechanisms for the production of VII*, in particular, alternative RNA splicing of the transcript from a single gene, cannot be excluded.
Introduction
Human coagulation Factor VII is a single-chain glycoprotein of -50,000 mol wt, present in plasma in trace quantities (1, 2) . It seems to be synthesized predominantly by the liver, and the production of a functional protein requires the posttranslational gamma carboxylation of specific glutamic residues located near the NH2-terminus of the molecule. Vitamin K is required for this modification to occur, and the gamma carboxyglutamic acid residues formed play an integral role in the binding of Factor of zymogen Factor VII as measured in a functional assay (7) . Whether zymogen, single-chain Factor (12) . The clinical courses in people with congenital deficiencies ofFactor VII have varied from mild bleeding diatheses to major hemorrhagic disorders with hemarthrosis and intracranial hemorrhage. In addition, anecdotal reports ofa possible thrombotic tendency have also appeared, and theoretical support for such events has been presented (8, (13) (14) (15) (16) .
Based on an inhibition neutralization assay using heterologous antisera to Factor VII, three immunologic variants ofFactor VII deficiency have been described (17) . In the VII-variant, detectable cross-reacting material (CRM)' is absent. In VIIR, CRM is present, but reduced, and in the VII+ variant a normal amount of CRM is present. Recently, a radioimmunoassay for Factor VII using specific heterologous antisera has been reported (18) . When this assay was applied to two commercially available Factor VII-deficient plasmas, both seemed to fall into the VIIR variant category.
Here, using two monoclonal antibodies raised against human Factor VII, we investigate the CRM status of three commercially available Factor VII-deficient plasmas. Further, the presence of an additional form of Factor VII CRM, not previously described in plasma, is documented. 1 . Abbreviations used in this paper: Con-A, Concanavalin A; CRM, crossreactive material; DFP, diisopropylfluorophosphate; DME, Dulbecco's modified Eagle's medium; endoglycosidase H, endo-fl-N-acetylglycosamidase; GK702 and 704, George King 702 and 704 plasma, respectively; MC, monoclonal anti-Factor VII antibody; MC-affigel, monoclonal antiFactor VII antibody coupled with affigel 10; PAGE, polyacrylamide gel electrophoresis; VII, Factor VII CRM with the same molecular weight Methods Materials. Affigel-IO and DEAE-affigel-Blue were purchased from BioRad Laboratories (Richmond, CA), and Sephacryl S-300 and Concanavalin-A-(Con-A)-Sepharose were obtained from Pharmacia Fine Chemicals (Piscataway, NJ). Soybean trypsin inhibitor, bovine serum albumin (BSA) Fresh human plasma was obtained from laboratory personnel. 9 vol of blood was drawn using the two-syringe technique into I vol of solution containing 10 mM diisopropylfluorophosphate (DFP), 50 mM EDTA, 1,000 U/ml aprotinin, 50 U/ml heparin, 100 gg/ml soybean trypsin inhibitor, 100 mM benzamidine, and 100 mM Tris-HCl, pH 8 After incubation for 2 h at 37°C, the clots were gently rimmed and serum was obtained after centrifugation at 4,000 g for 10 min.
Proteins. Factor VII was isolated and radiolabeled (1251) and a crude preparation of human brain thromboplastin was prepared as previously described (1, 7, 16 ). Factor VII was assumed to have an extinction coefficient (A, ,, at 280 nm) of 11.5 (16) . Thrombin was prepared from purified prothrombin (19) .
To produce chymotrypsin-treated VII, Factor (20) . Positive clones were selected using an enzyme-linked immunoadsorbent assay employing microtiter dishes coated with I ,ug/ml Factor VII, spent medium, and goat anti-mouse IgG linked to alkaline phosphatase (21). Positive clones were also tested in the same manner in the presence of 10 mM EDTA to determine if divalent metal ions were required for monoclonal antibody recognition of Factor VII.
Two clones, MC1476 (E.A. 8.1) and MC1839 (E.C. 3.3), were selected for further study. Large quantities ofeach were produced by the induction of peritoneal tumors in Balb/c mice (20) . The antibodies were purified from the subsequent ascitic fluid by ammonium sulfate precipitation and DEAE-affigel-Blue (Bio-Rad Laboratories, Richmond, CA) chromatography as described by the manufacturer.
The monoclonal antibodies were radiolabeled using Iodo-gen and carrier-free, sodium '251-iodide as previously described (16) . The specific radioactivity of the products varied from 1,000 to 4,000 dpm/ng IgG. (PAGE) . The procedure for MC1839 was the same with the exceptions that CaCI2 (final concentration, 25 mM) and heparin (final concentration, 5 U/ml) were added to the citrated plasma and the wash buffer contained 10 mM CaCI2. The same procedures were used to prepare samples from serum except the addition of CaCl2 and heparin were omitted.
SDS-PAGE was performed on 1.5-mm-thick slab gels using a 4% stacking gel and 10% separating gel in the buffer system of Laemmli (22) . Electrophoretic transfer to nitrocellulose was performed in the buffer system of Towbin et al. (23), using a Hoefer Transfer cell with a recirculating water bath ( 10°C) at 60 V for 90 min.
The nitrocellulose paper was "blocked" by incubation with 0.1 M NaCl, 0.05 M Tris-HCI, pH 7.5, 10 mg/ml BSA, and 0.6 mg/ml bovine IgG for I h at room temperature. Staining was then accomplished by the addition of radiolabeled '251-monoclonal antibody at a final concentration of0.2 Mg/ml and further incubation overnight with gentle agitation on a Junior Orbit Shaker (Lab-Line Instruments, Inc., Melrose Park, IL). The nitrocellulose paper was washed three times with 0.1 M NaCl, 0.05 M Tris-HCI, ph 7.5, dried with cool air, and placed in a cassette fitted with intensifying screens (Cronex; E. I. Du Pont de Nemours & Co., Inc., Wilmington, DE) with XAR-5 film (Eastman Kodak Co., Rochester, NY) for 4-24 h at -80°C. In the case of MC1839, 10 mM CaCI2 was also present in each buffer. For the purposes of this paper the term "Western blotting" will encompass the processes of SDS-PAGE, electrophoretic transfer of proteins from the polyacrylamide gel to nitrocellulose paper, and "staining" with radiolabeled antibody.
Infusion of VII into rabbits. 60 Mg of Factor VII or 251I-Factor VII (3,170 cpm/ng) in 200 Ml of0.1 M NaCI, 0.05 M Tris-HCI, pH 7.5, were infused into separate male New Zealand white rabbits (-3 kg) through the marginal ear vein ofthe right ear. Blood samples (1.5 ml) were drawn from the left ear into 50 Ml of 0.2 M EDTA (pH 7.0) at 8 min, 30 min, and 1, 2, 3, 4, 5, 6, and 8 h. The samples were immediately centrifuged at 12,000 g for 5 min and the plasma was frozen. The next day the plasma samples were thawed, and the Factor VII (or '25l-VII) absorbed and eluted from MC1476-affigel as previously described. The radioactive samples were reduced (5% 2-mercaptoethanol) and subjected to SDS-PAGE followed by autoradiography. The nonradioactive samples were processed through Western blotting as described above, and stained with '251-MC1476.
Partial purification ofFactor VII CRM in plasma. 1 U (240 ml) of fresh frozen plasma was passed through a 1-ml column of MC 1476-affigel at 10 ml/h at room temperature. The column was washed with 0.1 M NaCl, 0.005 M EDTA, 0.05 M Tris-HCl, pH 7.5, and eluted with 3 M NaSCN, 0.05 M Tris-HCl, pH 7.5 containing 0.1 mg/ml BSA at a flow rate of 2 ml/h. Fractions containing VII activity were pooled (5 ml), and dialyzed against 0.1 M NaCl, 0.05 M Tris-HC1, pH 7.5. The MC1476-affigel absorbed >99% of the VII activity and after elution, recovery of activity was 90%. 2-ml fractions of this partially purified VII/VII* were then dialyzed and passed through -I-ml columns ofMC1839-affigel (buffer HepG2 cell experiments. HepG2 cells were cultured in T-75 flasks,
with DME plus 4 mM L-glutamine, 10% fetal calf serum, and 1 Mg/ml vitamin K. The cells were allowed to proliferate to confluence. The medium was removed from the flasks and the adherent cells were washed gently twice with 15 ml of medium lacking fetal calf serum or vitamin K. The medium was then replaced with DME, 4 mM L-glutamine, and 1 Ag/ml vitamin K (four flasks) or DME, 4 mM L-glutamine, and 20 ,Mg/ml warfarin (two flasks). The cells were incubated overnight and then washed with the appropriate medium twice (15 ml each). To two of the flasks which had been incubated with vitamin K, 5 ml of the same medium was added. To the other set of two flasks that had been incubated with vitamin K, 5 ml of vitamin K containing medium plus '25I-VII (0.05 Mg/ml) was added. The two flasks incubated with warfarin received 5 ml each of the same medium. After incubation for an additional 24 h (370C, 5% CO2), the medium from each duplicate set of flasks was collected and pooled, a 1/10 volume of inhibitor cocktail (400 Mg/ml soy bean trypsin inhibitor, 0. The same method was used to obtain samples ofconditioned medium and cell lysates from HepG2 cells cultured with vitamin K for subsequent treatment with neuraminidase and endoglycosidase-H. After elution from MC1476-affigel the samples from conditioned medium and cell lysate were dialyzed against 0.02 M ammonium bicarbonate, divided into two equal portions, and Iyophilized. One ofthe lyophilized aliquots from the conditioned medium was resuspended in 40 Ml of0.05 M sodium acetate, pH 5.5, 0.145 M NaCl, 4 mM CaCI2, 50 mM benzamidine and the other was resuspended in 40 Ml ofthe same buffer with 1 U/ml neuraminidase. One of the Iyophilized aliquots from the lysed cells was suspended in 40
Ml of 50 mM sodium citrate, pH 5.5, and the other in 40 Ml of the same buffer with 50 mU/ml endoglycosidase-H. The samples were incubated overnight under toluene at 37°C and then subjected to SDS-PAGE and Western blotting as previously described.
Results
Characterizations ofantibodies. Several murine monoclonal antiFactor VII antibodies were produced using hybridoma technology. Two, MC 1476 and MC1839, were selected for further study. MC1476, an IgG1, recognized Factor VII in the presence or absence of divalent cations, while MC1839, an IgG2A, recognized Factor VII in the presence of 4 mM CaC12, but failed to bind Factor VII in the absence of divalent cations (5 mM EDTA). Within experimental error, both MC antibodies recognized Factor VII and VI1a with equal affinities and neither monoclonal anti-Factor VII antibody recognized CRM in dog, cow, or rabbit plasma (data not shown).
To determine the epitope specificity ofthe antibodies, western blots of purified Factor VII after activation by thrombin, or treatment with chymotrypsin were performed. Analysis of thrombin-treated Factor VII after reduction and SDS-PAGE revealed the heavy and light chains of Factor VI1a and an additional degradation product (Fig. 2, lane 8) . Both peared to require an epitope very near the NH2-terminus since it failed to recognize chymotrypsin-treated Factor VII (Fig. 3) . MC 1476, on the other hand, recognized an epitope distal to the chymotrypsin cleavage site of VII. These results are consistent with the previously noted calcium dependency of binding of MC1839 since for the other vitamin K-dependent factors thus far studied, chymotrypsin cleaves a 40-44-amino acid peptide from the NH2-terminus of these molecules, which contains all the gamma carboxyglutamic acid residues (e.g., [24] [25] [26] .
The apparent efficiency of '251-monoclonal antibody "staining" of VII or VIIa electrophoretically transferred from polyacrylamide gels to nitrocellulose was considerably decreased for both monoclonal antibodies if the proteins were reduced (5% 2-mercaptoethanol) before SDS-PAGE. Preliminary studies suggest that this phenomenon was not due to decreased transfer or absorption of protein to the nitrocellulose.
Western blots ofnative Factor VII in human plasmas. Technical problems arose when similar blotting experiments were attempted using samples of plasma. When sufficient quantities ofplasma were subjected to SDS-PAGE (-5 Ml) so that adequate "staining" of the electrotransferred Factor VII could be detected, distortion of the patterns due to large quantities of extraneous proteins (especially albumin) prevented meaningful interpretation. Barium citrate adsorption of the plasma and subsequent elution ofthe barium citrate pellet with ammonium sulfate were found to be effective means of concentrating and partially purifying the Factor VII before SDS-PAGE and Western blotting. However, not all the Factor VII CRM present in plasma bound to barium citrate (see below). Therefore, for the remaining studies, the plasma Factor VII was partially purified and concentrated by affinity absorption to monoclonal antibody linked to affigel-10 (MC-affigel). After elution from the gel with SDS, the proteins were subjected to SDS-PAGE, electrophoretic transfer to nitrocellulose, and "staining" with radiolabeled monoclonal antibody. Under the conditions noted in Methods, 90% of 25I-Factor VII (0.5 gg/ml) added to plasma was absorbed by MC 1476 affigel, and 80% by MC1839 affigel in 1 h. Fig. 4 shows the results of western blots using George King 702 (GK702) and 704 (GK704) and Dade Factor VII-deficient plasmas. Neither MC1476 nor MC1839 detected CRM in GK702 plasma and the amount of CRM in GK704 and Dade plasmas appeared to be reduced from that of normal human plasma. In control experiments the level of Factor VII that could be detected by these methods was determined by adding various concentrations of purified Factor VII (or pooled normal human plasma assumed to contain 100% Factor VII) to GK702 plasma. Adsorption and staining using MC1476 could detect <0.0039 ,gg/ml (<0.8%) Factor VII, and adsorption and staining with MC1839 -0.0313 ug/ml (-6.25%) Factor VII. When plasma was absorbed using MC1839-affigel and then 1251-MC1476 was used to stain the subsequent blot, 0.0078 ug/ml Factor VII (1.56%) could be detected. As determined by their recognition by these two monoclonal antibodies, GK702 was CRM-, GK704 was CRMR, and Dade was CRMR for Factor VII (see Discussion).
The apparent functional activity of the Factor VII in each deficient plasma was evaluated using human, rabbit, or bovine brain thromboplastins (Table I ). GK702 and Dade Factor VIIdeficient plasmas had <1% functional activity compared with pooled normal plasma no matter which species of thromboplastin was employed. GK704 plasma, however, demonstrated considerable Factor VII functional activity when human or bovine thromboplastin was used. Using the monoclonal "sandwich" immunoassay described in Methods, GK702 plasma contained <1% (measured consistently less than the Factor VII immuno-depleted plasma), GK704 plasma contained 45%, and Dade (Fig. 4) . This band "stained" A BE ci 5 6 with a lower intensity, and frequently appeared as a doublet with a molecular weight of -4,500 D less than purified Factor VII. This form ofFactor VII CRM, tentatively named VII*, was not detected by MCl 839 (Fig. 4 , B and C). Its presence was not due to proteolysis during the blotting procedure itself since fresh plasma drawn and prepared for Western blotting using a host _161, of inhibitors (see Methods) contained comparable amounts of Factor VII* to pooled normal plasma (Fig. 4, lanes 1 and 7) and GK702 plasma reconstituted with purified Factor VII (0.5 ,ug/ml) (or VIla, data not shown) and processed for Western blotting in the absence of inhibitors failed to contain detectable VII* (Fig. 4, lane 3) . Although the presence of VII* did not seem to be due to artifactual proteolysis of Factor VII during the sample preparation for blotting, it remained possible that it was the result of intravascular proteolysis. However, when GK702 plasma was reconstituted with Factor VII (0.5 ug/ml) and induced to clot in the presence of phospholipids and Ca"+ by the addition of a glass surface, Russell's viper venom, or human brain thromboplastin, VII* was not formed. The When plasma was treated with barium citrate, most of the psin-treated Factor VII was absorbed to the barium salt while the VII* remained in )o VII 2 g, l the supernatant (Fig. 5, lanes 1 and 2) . VII* appeared to be a lestern blot using single-chain protein since its mobility on SDS-PAGE was not I-MC1839, lanes 5 affected by treatment with 5% 2-mercaptoethanol (Fig. 5 , lanes 3 and 4). As noted previously, the efficiency of '251I-monoclonal VII and VII* were partially purified by affinity chromatography on MC1476-affigel (Methods) from fresh frozen plasma (Fig. 5, lane 6) . As determined by Western blotting using 125I-MC 1476, the passage of this material through MC1839-affigel yielded VII* and reduced amounts of VII (Fig. 5, Fig. 7 . Two sets of Western blots were performed. In the first hanol before SDS-PAGE. Lane MCI 839 detectable CRM fell rapidly to a level of -2% (Fig. 7, 942 G. J. Broze, Jr., S. Hickman, and J. P. Miletich C). VII detected by MC 1476, however, never fell below 20%. VII* was detectable throughout the course of the experiment, and its level relative to that of VII (as recognized by MC 1476) increased from -7% before warfarin treatment to >35% at the nadir of Factor VII functional activity.
After warfarin treatment, MCl 839 did not detect the same quantity of CRM that was recognized by MC 1476. This is consistent with MC I 839's requirement for divalent cations and the NH2-terminus of Factor VII since, presumably, the Factor VII synthesized under the influence of warfarin possesses decreased or absent gamma-carboxyglutamic acid residues. Production of VII and VII* by HepG2 cells. The human hepatocellular carcinoma cell line HepG2 has been shown to produce prothrombin and Factor X (27) . Conditioned medium (24 h) and cell lysates were obtained from confluent cultures of HepG2 cells that had been grown in the presence of vitamin K or warfarin and prepared for Western blotting using MC1476 as described in Methods. To quantitate the relative amounts of VII and VII* the appropriate areas of the nitrocellulose blot were cut out and their radioactivity determined by gamma counting. The conditioned medium from HepG2 cells cultured in the presence of vitamin K contained both VII and VII* ( 8, lane 3) and the quantity of VII* was 75% of that of Factor VII, a level considerably higher than the 5-8% noted in human plasma (Fig. 7) . The conditioned medium from the warfarintreated cells (Fig. 8 , lane 5) contained markedly reduced amounts of VII (23%) but only slightly reduced amounts of VII* (86%) when compared with the conditioned medium from cells cultured in the presence ofvitamin K (Fig. 8, lane 3) . Western blots of intracellular material obtained by detergent lysis of the cells revealed several similar bands in both vitamin K and warfarin treated cells (Fig. 8, lanes 4 and 6) . Control experiments in which '251-VII was added to the cell cultures (Fig. 8, lane 1) or to the cells at the time of detergent lysis (not shown) failed to detect proteolytic cleavage ofthe radiolabeled VII under the same conditions. VII and VII* contain asparagine-linked oligosaccharides since both were bound by Con-A Sepharose (Fig. 5, lane 7) . To further investigate the carbohydrate content of the Factor VII CRM, conditioned medium and cell lysates from HepG2 cells cultured in the presence of vitamin K were treated with neuraminidase (cleavage of terminal sialic residues (28) or endoglycosidase-H (cleavage of high mannose-type oligosaccharides) (29) (Fig. 9) . The apparent molecular weight of both Factor VII and VII* isolated from conditioned medium was reduced after neuraminidase treatment, demonstrating that they both contain sialic acid residues. Endoglycosidase-H treatment of these secreted proteins had no effect on the Factor VII CRM, suggesting that the Factor VII and VII* asparagine-linked oligosaccharides are of the complex-type (data not shown). It is known that asparagine-linked oligosaccharides ofthe complex-type are initially high mannose-type structures before extensive intracellular carbohydrate processing (30) . After endoglycosidase-H treatment of the cell lysate proteins, the four major bands ofFactor VII CRM were consolidated into two bands suggesting that the intracellular heterogeneity of Factor VII and VII* is the result of varying degrees of oligosaccharide processing. As shown in Fig. 9 The monoclonal sandwich assay for Factor VII described using MC 1476 and MC1839 is simple and convenient. It is faster, and at least as sensitive as the competitive radioimmunoassay that has been previously reported (18) . Since the sandwich assay employs MC 1839, however, it does not detect VII* or the gamma carboxyglutamate-deficient Factor VII synthesized under the influence of warfarin (Figs. 4 and 7) . Indeed, additional experiments (not shown) have confirmed a very close correlation between immunologic levels of Factor VII measured by this monoclonal sandwich assay and functional Factor VII activity after warfarin therapy in the experiment noted in Fig. 7 (correlation coefficient, 0.982).
Interestingly, GK704 plasma produced differing apparent functional levels of Factor VII depending upon the species of thromboplastin used in the assay. The species specificity of the Factor VII-tissue factor interaction is well known, and variant Factor VII molecules with different patterns of "activation" with human, rabbit, and bovine brain thromboplastins have been described (31-33). GK704 plasma expressed the greatest relative activity with bovine brain (30%) > human brain (11%) > rabbit brain (1.4%), a pattern similar to that reported for the Padua, Factor (34) have demonstrated that treatment of bovine Factor VII with Factor Xa led to its inactivation by proteolytic degradation. This process involved the proteolytic cleavage of a 12,500-Dalton polypeptide, containing the active serine site, from the heavy chain of bovine Factor VIIa. Thus, a similar mechanism would not appear to explain the presence of VII* in human plasma. Treatment ofpurified human Factor VII with relatively high levels of thrombin (5% wt/wt) also produced a degradation product (Fig. 2) . Its posible relationship to VII*, however, remains unclear.
Our attempts to produce VII* from purified Factor VII (or 125I-VII) in vitro by clotting of blood or plasma, or in vivo by infusion into rabbits were unsuccessful. Furthermore, experiments studying the production of VII by human hepatoma cells suggest that if VII* is produced by proteolytic processing of VII, this occurs intracellularly. Similar apparent intracellular proteolysis ofother vitamin K-dependent factors (prothrombin and Factor X) synthesized by HepG2 cells has not been described. VII* is not a precursor of VII which has not been glycosylated since it binds to Con-A Sepharose (as does VII), contains sialic acid, and exists intracellularly in forms containing high mannosetype oligosaccharides. Interestingly, while warfarin treatment of HepG2 cells inhibited the secretion of Factor VII, it seemed to have little effect upon the secretion of VII*. The immunological studies in the patient on chronic warfarin therapy (Fig. 4, lane  6 ) and the individual given a short course of high dose warfarin treatment (Fig. 7) corroborate this phenomenon. These immunological studies also suggest that the discrepancy between Factor VII antigen and activity measurements which has been noted in patients undergoing warfarin therapy (18, 35, 36) may not only be due to the production ofFactor VII molecules lacking their full complement of gamma carboxyglutamic acids, but also may be due in part to the relative increase in VII* to VII CRM.
The ratio of VII*/VII produced by HepG2 cells (75%) was much greater than that found in normal human plasma (5-8%). Whether this discrepancy is due to differential clearance of plasma VII and VII* in vivo, the artificial in vitro culture system employed, or the phenotype of the HepG2 cells themselves, can not be determined.
Although posttranslational proteolytic degradation of VII is a likely mechanism for the production of VII*, other explanations are possible; in particular, alternative RNA splicing of the transcript from a single gene (37) (38) (39) (40) . Purification of VII* is now under way to permit further studies concerning its structure, function, and relationship to Factor VII.
